Nathaniel Katz, MD, MS
Dr. Katz is President of Analgesic Solutions, a consulting firm focused on analgesics. Dr. Katz is also Adjunct Assistant Professor of Anesthesia at Tufts University School of Medicine. After completing his neurology residency at Tufts-New England Medical Center he entered a Pain Management fellowship in the Department of Anesthesia at Brigham & Women’s Hospital in 1990. After which Dr. Katz was appointed Staff Neurologist in the Pain Management Center of Brigham & Women’s Hospital. Subsequently, he founded the Pain & Symptom Management Program at Dana Farber Cancer Institute, and the Pain Trials Center (a clinical analgesics research unit) at Brigham & Women’s Hospital. He remained Director of both until 2001. From 2000-2004 Dr. Katz served as Chair of the Advisory Committee, Anesthesia, Critical Care, and Addiction Products Division, United States Food and Drug Administration, during which time he completed a Master of Science degree in Biostatistics at Columbia University. Dr. Katz’s interests include clinical research methods, analgesic clinical trials, opioids for chronic pain, opioids and addiction, neuropathic pain, and cancer pain. He has completed numerous clinical trials of treatments for pain, both industry-initiated and investigator-initiated, involving pharmaceuticals, non-pharmaceutical analgesics and devices, and has also conducted studies related to opioids, pain, addiction, and other issues related to opioid therapy. Dr. Katz is active on many publications and was an Associate Editor at the Clinical Journal of Pain, and Associate Editor (Pain) for the Encyclopedia of Neurological Sciences, and has overseen many local and national educational programs on pain management.
Paul Goldenheim, MD
Dr. Goldenheim is trained as a pulmonary physician and is currently working as a director and consultant in the field of biotechnology, serving on the boards of directors of several companies (including BIND, Promedior, and Hydra Biosciences). He has a long history in pharmaceutical research, development, regulatory strategy, and management, most recently as president of TransForm Pharmaceuticals (acquired by Johnson & Johnson) and Vice Chairman of the Board of Directors of Hypnion (acquired by Eli Lilly). Dr. Goldenheim has considerable experience in the evaluation and development of analgesics, having been an Executive Vice President of Research and Development and Chief Science Officer at Purdue Pharma. He has authored numerous scientific publications and been an inventor on a number of pharmaceutical patents. He received his AB from Harvard College magna cum laude with highest honors in biochemical sciences and his MD from Harvard Medical School.
Kevin Flynn, Director
Director, Scientific Communications
Kevin has over 20 years of experience in medical communications, with a focus on publication planning and writing. Kevin began his career as a copyeditor at MD Anderson Cancer Center, editing basic science manuscripts. He later moved on to pharmaceutical sales training, writing for CME programs, and later publication development (clinical papers and reviews), primarily in oncology, pain management, bipolar disorder, insomnia, and disorders of excessive sleepiness. He provided extensive KOL development services for Cephalon in both their pain and sleep-wake franchises, designing and coordinating advisory boards in both areas. Kevin is former president of the New England and Southwest chapters of the American Medical Writers Association, a former member of the AMWA Executive Council, and an active workshop leader at annual AMWA conferences. He is a published author on ghostwriting (Flynn K. Controversy continues about contributions of medical writers. AMWA Journal. 2006;21:56-60) and publication standards (Bareket-Samish et al. Good publication practice guidelines for medical communications agencies: a MedComm perspective. Current Medical Research and Opinion. 2009;25(2):453-461).
Richard G. Van Inwegen, PhD
Director of Operations
Richard has a Ph.D. in physiology with post-doctoral research in Pharmacology. He spent 13 years in research/drug discovery and 15 plus years in drug development with small pharmaceutical companies covering multiple functions including clinical, toxicology, pharmacokinetics, regulatory, program management and strategic planning. He has been involved in a wide variety of therapeutic areas, including anti-infectives, asthma, cardiovascular, dermatology, endocrinology, inflammation, oncology and women’s health care (osteoporosis and hormone replacement). He has authored numerous scientific abstracts and presentations, peer reviewed publications, pre-clinical and clinical study protocols and reports, and regulatory filings, including INDs, NDAs, annual reports, package inserts.
Jeremiah J. Trudeau, PhD
Director of Psychometrics
Dr. Trudeau holds a B.A. in Cognitive Psychology from Hampshire College and a Ph.D. in Experimental Psychology from the University of Connecticut. Dr. Trudeau is focused on the cognitive and perceptual aspects of the pain experience from a patient perspective. He believes that the best reflection of analgesic efficacy is in the patient’s subjective experience. His past research has included bringing innovative research methods to the perception of language using artificially manufactured stimuli and the novel use of advanced statistical techniques in the exploration of embodied cognition. He also has several years of experience as a team leader and project manager from his time working in Information Technology prior to his academic career.